Inactive Instrument

Hubei Minkang Pharmaceutical Ltd.

HBMK

US44352W1018

Hubei Minkang Pharmaceutical Ltd announced that it has received $0.79 million in funding.

May 15, 2012 at 12:00 am EDT

Hubei Minkang Pharmaceutical Ltd (OTCBB:HBMK) announced a private placement of 1,130,270 common shares at $0.70 per share for gross proceeds of $791,189 on May 15, 2012. On May 15, 2012, Hubei Minkang Pharmaceutical Ltd closed the transaction.

Latest news about Hubei Minkang Pharmaceutical Ltd.

Hubei Minkang Pharmaceutical Ltd cancelled the acquisition of 51% stake in Henan Wanlong Pharmaceutical Co., Ltd.	13-06-27	CI
Hubei Minkang Pharmaceutical Ltd. Announces Management Changes	13-06-24	CI
Hubei Minkang Pharmaceutical Ltd cancelled the acquisition of 51% stake in Hubei Merryclin Pharmaceuticals Co., Ltd.	13-03-27	CI
Hubei Minkang Pharmaceutical Ltd announced that it has received $0.79 million in funding.	12-05-15	CI
Hubei Minkang Pharmaceutical Ltd signed a memorandum of understanding to acquire up to 51% stake in Hubei Merryclin Pharmaceuticals Co., Ltd.	12-03-27	CI
Hubei Minkang Pharmaceutical Ltd signed a memorandum of understanding to acquire 51% stake in Henan Wanlong Pharmaceutical Co., Ltd.	12-02-28	CI
Hubei Minkang Pharmaceutical Ltd will Change its Ticker to HBMK from HBMK.E	12-02-22	CI
Hubei Minkang Pharmaceutical Ltd will Change its Ticker to HBMKE from HBMK	12-02-21	CI

Chart Hubei Minkang Pharmaceutical Ltd.

Duration

Period

More charts

Company Profile

Hubei Minkang Pharmaceutical Ltd. (Hubei), through its subsidiaries, HBMK Pharmaceutical Limited (HBMK) and Hubei Minkang PRC, produces and markets traditional Chinese medicines (TCM). The Company's products include product types include pills, tablets, capsules, granules, oral liquids, syrups, mixtures and injections and dosages. It markets its products to the United States, Japan, Canada, Singapore, Malaysia, Thailand and Hong Kong. The Company's principal Chinese products include Yinxing Damo Zhusheye, An Ka Huangmin Jiaonang, Xumeian Capsule, Wei C Yinqiao Pian and Shuxin Koufouye. Hubei Minkang PRC's selling product, Wei C is approved by the United States Food and Drug Administration (FDA) for sale in the United States. Hubei Minkang PRC markets its products in approximately 26 provinces in China, and has a distribution network which covers over 1200 hospitals and 10100 medical halls (TCM pharmacies).

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals